These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 15273242)
61. Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease. Leonard AD; Thompson JP; Hutchinson EL; Young SP; McDonald J; Swanevelder J; Lambert DG Br J Anaesth; 2009 Apr; 102(4):477-84. PubMed ID: 19258379 [TBL] [Abstract][Full Text] [Related]
62. Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway. Zhao J; Miao G; Wang T; Li J; Xie L Life Sci; 2020 Dec; 262():118551. PubMed ID: 33038370 [TBL] [Abstract][Full Text] [Related]
63. TRPC1 expression and distribution in rat hearts. Huang H; Wang W; Liu P; Jiang Y; Zhao Y; Wei H; Niu W Eur J Histochem; 2009 Dec; 53(4):e26. PubMed ID: 22073358 [TBL] [Abstract][Full Text] [Related]
64. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Dschietzig T; Bartsch C; Pregla R; Zurbrügg HR; Armbruster FP; Richter C; Laule M; Romeyke E; Neubert C; Voelter W; Baumann G; Stangl K Regul Pept; 2002 Dec; 110(1):33-8. PubMed ID: 12468107 [TBL] [Abstract][Full Text] [Related]
65. Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling. Fontes-Sousa AP; Brás-Silva C; Pires AL; Monteiro-Sousa D; Leite-Moreira AF Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):107-15. PubMed ID: 17701026 [TBL] [Abstract][Full Text] [Related]
66. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Douglas SA; Ohlstein EH Trends Cardiovasc Med; 2000 Aug; 10(6):229-37. PubMed ID: 11282300 [TBL] [Abstract][Full Text] [Related]
67. The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure. Nishi M; Tagawa H; Ueno M; Marumoto S; Nagayama T Heliyon; 2020 Feb; 6(2):e03352. PubMed ID: 32055741 [TBL] [Abstract][Full Text] [Related]
68. UII/GPR14 is involved in NF-κB-mediated colonic inflammation in vivo and in vitro. Yang Y; Zhang J; Chen X; Wu T; Xu X; Cao G; Li H; Li Y Oncol Rep; 2016 Nov; 36(5):2800-2806. PubMed ID: 27600191 [TBL] [Abstract][Full Text] [Related]
69. Mechanical restitution and recirculation fraction in cardiac myocytes and left ventricular muscle of adult rats. Ravens U; Mahl C; Ohler A; Hardman SM; Noble MI Basic Res Cardiol; 1996; 91(2):123-30. PubMed ID: 8740528 [TBL] [Abstract][Full Text] [Related]
70. Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart. Doan ND; Nguyen TT; Létourneau M; Turcotte K; Fournier A; Chatenet D Br J Pharmacol; 2012 May; 166(1):243-57. PubMed ID: 22044114 [TBL] [Abstract][Full Text] [Related]
71. Quantification of the voltage-response relationship between punctate and field electrical stimulation and the function of isolated rat left atria and papillary muscles. Olson RD; Vestal RE; Mendenhall WA; Mudumbi V J Pharmacol Toxicol Methods; 1995 Dec; 34(4):225-30. PubMed ID: 8785426 [TBL] [Abstract][Full Text] [Related]
72. Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Vergura R; Camarda V; Rizzi A; Spagnol M; Guerrini R; Calo' G; Salvadori S; Regoli D Naunyn Schmiedebergs Arch Pharmacol; 2004 Nov; 370(5):347-52. PubMed ID: 15526105 [TBL] [Abstract][Full Text] [Related]
73. Evidence for MOR on cell membrane, sarcoplasmatic reticulum and mitochondria in left ventricular myocardium in rats. Treskatsch S; Shaqura M; Dehe L; Roepke TK; Shakibaei M; Schäfer M; Mousa SA Heart Vessels; 2016 Aug; 31(8):1380-8. PubMed ID: 26686371 [TBL] [Abstract][Full Text] [Related]
74. Identification of potential pharmacological targets by analysis of the comprehensive G protein-coupled receptor repertoire in the four cardiac chambers. Moore-Morris T; Varrault A; Mangoni ME; Le Digarcher A; Negre V; Dantec C; Journot L; Nargeot J; Couette B Mol Pharmacol; 2009 May; 75(5):1108-16. PubMed ID: 19229040 [TBL] [Abstract][Full Text] [Related]
75. Isolated neonatal rat papillary muscles: a new model to translate neonatal rat myocyte signaling into contractile mechanics. Nizamutdinov D; Feng H; Gerilechaogetu F; Dostal JA; Foster DM; Glaser SS; Dostal DE Physiol Rep; 2016 Feb; 4(3):. PubMed ID: 26869681 [TBL] [Abstract][Full Text] [Related]
76. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. Douglas SA; Ashton DJ; Sauermelch CF; Coatney RW; Ohlstein DH; Ruffolo MR; Ohlstein EH; Aiyar NV; Willette RN J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S163-6. PubMed ID: 11078367 [TBL] [Abstract][Full Text] [Related]
78. An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts. Liu W; Han Q; Liu Q; Liang G; Wang J; Liu C Mol Med Rep; 2015 Nov; 12(5):6626-34. PubMed ID: 26323194 [TBL] [Abstract][Full Text] [Related]
79. Expression of the subtype 1A dopamine receptor in the rat heart. Ozono R; O'Connell DP; Vaughan C; Botkin SJ; Walk SF; Felder RA; Carey RM Hypertension; 1996 Mar; 27(3 Pt 2):693-703. PubMed ID: 8613227 [TBL] [Abstract][Full Text] [Related]
80. Annexin V in the adult rat heart: isolation, localization and quantitation. Jans SW; van Bilsen M; Reutelingsperger CP; Borgers M; de Jong YF; van der Vusse GJ J Mol Cell Cardiol; 1995 Jan; 27(1):335-48. PubMed ID: 7760355 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]